MNK1/2 Inhibition Limits Oncogenicity and Metastasis of KIT-mutant Melanoma

Yao Zhan,Jun Guo,William Yang,Christophe Goncalves,Tomasz Rzymski,Agnieszka Dreas,Eliza Żyłkiewicz,Maciej Mikulski,Krzysztof Brzózka,Aniela Golas,Yan Kong,Meng Ma,Fan Huang,Bonnie Huor,Qianyu Guo,Sabrina Daniela da Silva,Jose Torres,Yutian Cai,Ivan Topisirovic,Jie Su,Krikor Bijian,Moulay A Alaoui-Jamali,Sidong Huang,Fabrice Journe,Ghanem E Ghanem,Wilson H Miller,Sonia V Del Rincón

DOI: https://doi.org/10.1172/jci181338

2024-01-01

Abstract:Melanoma can be stratified into unique subtypes based on distinct pathologies. The acral/mucosal melanoma subtype is characterized by aberrant and constitutive activation of the proto-oncogene receptor tyrosine kinase C-KIT, which drives tumorigenesis. Treatment of these melanoma patients with C-KIT inhibitors has proven challenging, prompting us to investigate the downstream effectors of the C-KIT receptor. We determined that C-KIT stimulates MAP kinase–interacting serine/threonine kinases 1 and 2 (MNK1/2), which phosphorylate eukaryotic translation initiation factor 4E (eIF4E) and render it oncogenic. Depletion of MNK1/2 in melanoma cells with oncogenic C-KIT inhibited cell migration and mRNA translation of the transcriptional repressor SNAI1 and the cell cycle gene CCNE1. This suggested that blocking MNK1/2 activity may inhibit tumor progression, at least in part, by blocking translation initiation of mRNAs encoding cell migration proteins. Moreover, we developed an MNK1/2 inhibitor (SEL201), and found that SEL201-treated KIT-mutant melanoma cells had lower oncogenicity and reduced metastatic ability. Clinically, tumors from melanoma patients harboring KIT mutations displayed a marked increase in MNK1 and phospho-eIF4E. Thus, our studies indicate that blocking MNK1/2 exerts potent antimelanoma effects and support blocking MNK1/2 as a potential strategy to treat patients positive for KIT mutations.